CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02362035
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:51.014774+00:00
Published At: 2022-05-06T00:00:00+00:00
Record Updated At: 2025-12-11
Results Posted At: 2022-05-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Follicular Lymphoma (FL)", "CLL", "Small Lymphocytic Lymphoma (SLL)", "Richter\u0027s Syndrome", "Mantle Cell Lymphoma (MCL)", "Indolent Non Hodgkin Lymphoma", "Waldenstr\u00f6m Macroglobulinemia", "Multiple Myeloma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Marginal Zone Lymphomas", "Mediastinal Large B Cell Lymphoma", "Hairy Cell Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-12-11"
protocolSection.identificationModule.nctId: "NCT02362035"
protocolSection.identificationModule.officialTitle: "A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-05-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.